Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective trimmed by Chardan Capital from $22.00 to $20.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on LXEO. Royal Bank of Canada decreased their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Finally, Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $21.80.

Lexeo Therapeutics Trading Up 7.6%

Shares of Lexeo Therapeutics stock opened at $2.83 on Tuesday. The company has a fifty day simple moving average of $3.06 and a 200-day simple moving average of $5.08. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a market cap of $93.95 million, a price-to-earnings ratio of -0.90 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19). On average, equities analysts forecast that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of large investors have recently made changes to their positions in the stock. Ground Swell Capital LLC purchased a new position in shares of Lexeo Therapeutics in the 1st quarter valued at about $80,000. Nuveen LLC purchased a new position in shares of Lexeo Therapeutics in the 1st quarter valued at about $125,000. Privium Fund Management B.V. increased its holdings in shares of Lexeo Therapeutics by 16.0% in the 1st quarter. Privium Fund Management B.V. now owns 160,198 shares of the company’s stock valued at $556,000 after purchasing an additional 22,083 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock valued at $507,000 after purchasing an additional 25,089 shares in the last quarter. Finally, Woodline Partners LP grew its stake in Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock valued at $5,650,000 after acquiring an additional 6,730 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.